Pacira BioSciences Posts 73c Adj EPS in Q2, Beating Expectations
PCRX sits 47% above its 52-week low of $18.8 on elevated volume (2.1× avg).
Summary
Pacira BioSciences reported Q2 adjusted EPS of 73 cents, a strong result that comes amid an ongoing proxy battle with activist investor DOMA Perpetual. The earnings beat provides fresh ammunition for management's defense, following a series of proxy filings and endorsements from ISS and Glass Lewis. With the stock trading near its 52-week high, this print reinforces the turnaround narrative the board has been pitching to shareholders. The company has also been actively buying back stock, with a $200M program announced earlier this year. No revenue or guidance details were provided in the headline, but the EPS figure alone is likely to move the stock.
At the time of this announcement, PCRX was trading at $27.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $18.80 to $27.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.